Immutep Quarterly Activities Report Q4 FY25

SEC Filing 6-K (0001193125-25-169631)

Immutep Limited provided an update on its activities for the quarter ended June 30, 2025. The pivotal TACTI-004 Phase III trial in first-line non-small cell lung cancer (1L NSCLC) continues to recruit patients across 78 sites in 23 countries. The INSIGHT-003 trial reported a 60.8% response rate and 90.2% disease control rate in 1L NSCLC patients. In head and neck cancer, the TACTI-003 trial achieved a median overall survival of 17.6 months in patients with PD-L1 expression below one. The EFTISARC-NEO Phase II trial in soft tissue sarcoma met its primary endpoint. Immutep also reported positive initial efficacy data from the Phase I trial of IMP761, a LAG-3 agonist antibody for autoimmune diseases. The company has a strong cash position of A$129.69 million, expected to fund operations through the end of 2026.